ArticleHeliyon2025
Livogrit mitigates ANIT-induced cholestasis-like symptoms in an
Article in Heliyon, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Livogrit Ameliorates Thioacetamide-Induced Liver Fibrosis and Dyslipidemia in Rat Model by Regulating Oxidative Stress and Hepatic Collagen Levels, in a Non-Mutagenic Manner.Journal of experimental pharmacology · 2026Article
- "Top-down and Bottom-up" cholesterol-depleting biomimetic nanoparticle for enhancing sonodynamic therapy against hepatocellular carcinoma.Materials today. Bio · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bile duct constriction disrupts bile acid flow causing cholestasis, hepatic necrosis, fibrosis, and cirrhosis. The study investigated hepatoprotective effectiveness of Ayurvedic prescription herbal medicine "Livogrit" commercially available in India, against α-naphtylisothiocyanate (ANIT)-induced cholestasis-like symptoms in male Sprague-Dawley rats. Livogrits's phytochemical profiling showed the presence of Gallic acid, Methyl Gallate, Catechin, Corilagin, Ellagic acid, Rutin, and Cinnamic acid. Sprague-Dawley rats were pre-treated with Livogrit (20-600 mg/kg/day) and reference drug Ursodeoxycholic acid (100 mg/kg/day) for 15 and 5 days, respectively, before single-dose ANIT (100 mg/kg) stimulation. Livogrit treatment protect the rats against ANIT-induced increase in blood serum markers (total bile acids, ALT, AST, GGT, ALP, total cholesterol, and total bilirubin) and reduced manifestation of liver necrosis, inflammation, and periportal fibrosis. At molecular level, Livogrit inhibited up-regulation of BAX, TGF-β, α-SMA, and MMP-9 mRNA expressions, associated with the liver damages. Taken together, this study supported Livogrit's potential as hepatoprotective medicine against cholestasis-like-etiologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.